What is the level of liabilities of OncoCyte this year?
OncoCyte has a debt balance of 49.3 M USD this year.
OncoCyte Liabilities 2024
OncoCyte Liabilities
49.3 M USD
Ticker
OCX
ISIN
US68235C1071
WKN
A2ACBH
In 2024, OncoCyte's total liabilities amounted to 49.3 M USD, a -18.52% difference from the 60.5 M USD total liabilities in the previous year.
OncoCyte Aktienanalyse
What does OncoCyte do?
OncoCyte Corp is a company based in Alameda, California, that is involved in the field of cancer diagnostics. It was founded in 2009 with the goal of developing and commercializing innovative solutions for cancer diagnosis. The business model of OncoCyte Corp is based on the development and marketing of diagnostic tests for various types of cancer. The company focuses on identifying biomarkers that enable accurate and reliable diagnosis. The tests developed by OncoCyte Corp can be used for both early detection and monitoring of cancer patients. OncoCyte Corp is divided into several divisions, each specialized in developing products for specific types of cancer. These divisions include breast cancer, lung cancer, bladder cancer, and ovarian cancer. Each division is led by an expert team with extensive knowledge and experience in the respective area. One of the key products of OncoCyte Corp is the DetermaRx™ test, specifically developed for lung cancer. This test identifies specific biomarkers that provide a prognosis regarding the response to chemotherapy. The DetermaRx™ test is currently in clinical trials and could be used in the future to aid in the decision-making process for selecting the appropriate treatment method for lung cancer patients. Another product of OncoCyte Corp is the DetermaDx™ test, specifically developed for the early detection of breast cancer. This test utilizes a combination of biomarker-based tests and imaging techniques to detect cancer cells at an early stage. The DetermaDx™ test is currently undergoing validation and could potentially become a standard diagnosis for breast cancer in the future. OncoCyte Corp has also formed several partnerships with pharmaceutical and diagnostic companies to promote the development and commercialization of its products. One such partnership exists with Life Technologies Corporation, a globally leading company in the field of diagnostics and analytics. OncoCyte Corp strives to develop and bring to market innovative solutions for cancer diagnosis. With its vast resources and experienced team of scientists, the company has the potential to change the way cancer is diagnosed and treated. OncoCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing OncoCyte's Liabilities
OncoCyte's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating OncoCyte's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing OncoCyte's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
OncoCyte's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in OncoCyte’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about OncoCyte Stock
What were the liabilities of OncoCyte compared to the previous year?
The liabilities of OncoCyte have increased by -18.52% dropped compared to the previous year.
What are the consequences of high debt for investors of OncoCyte?
High liabilities can pose a risk for investors of OncoCyte, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in OncoCyte?
Low liabilities mean that OncoCyte has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of OncoCyte affect the company?
An increase in liabilities of OncoCyte can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of OncoCyte affect the company?
A decrease in the liabilities of OncoCyte can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of OncoCyte?
Some factors that can influence the liabilities of OncoCyte include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of OncoCyte so important for investors?
The liabilities of OncoCyte are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can OncoCyte take to modify the liabilities?
To change its liabilities, OncoCyte can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does OncoCyte pay?
Over the past 12 months, OncoCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoCyte is expected to pay a dividend of 0 USD.
What is the dividend yield of OncoCyte?
The current dividend yield of OncoCyte is .
When does OncoCyte pay dividends?
OncoCyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of OncoCyte?
OncoCyte paid dividends every year for the past 0 years.
What is the dividend of OncoCyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is OncoCyte located?
OncoCyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von OncoCyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of OncoCyte from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.
When did OncoCyte pay the last dividend?
The last dividend was paid out on 6/30/2024.
What was the dividend of OncoCyte in the year 2023?
In the year 2023, OncoCyte distributed 0 USD as dividends.
In which currency does OncoCyte pay out the dividend?
The dividends of OncoCyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von OncoCyte
Our stock analysis for OncoCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
